Intrinsic and acquired drug resistance severely limits the efficacy and response duration of anticancer therapies. Contributing to drug resistance are the existence of self-renewing stem cell populations, heterogeneity of tumour genomes and the ability of cancer cells to engage compensatory or redundancy mechanisms. The downloads included in this Drug Discovery Today Editor’s Choice newsletter outline progress in our understanding of stem cell biology, emerging technologies for high content imaging and molecular pathway profiling of tumours, and the importance of collaboration between industrial and academic translational researchers
16 August, 2013
The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
01 August, 2013